Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10369144B2 · kind B2 · utility
6Cited by
22References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2019 |
| Grant date | Aug 6, 2019 |
| Priority date | — |
| Expiry date | Feb 28, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides a method of treating a central nervous system disorder in a patient in need thereof. The method comprises orally administering between 75 mg and 300 mg xanomeline and between 20 mg and 200 mg trospium chloride to the patient during a 24-hour period. The central nervous system disorder is selected from schizophrenia, Alzheimer's disease, Huntington's disease, Parkinson's disease, and Lewy Body dementia, wherein use of the trospium chloride alleviates a side effect associated with use of the xanomeline.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.